{"id":"https://openalex.org/W2317247348","doi":"https://doi.org/10.1136/annrheumdis-2012-eular.724","title":"AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects","display_name":"AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects","publication_year":2012,"publication_date":"2012-06-01","ids":{"openalex":"https://openalex.org/W2317247348","doi":"https://doi.org/10.1136/annrheumdis-2012-eular.724","mag":"2317247348"},"language":"en","primary_location":{"id":"doi:10.1136/annrheumdis-2012-eular.724","doi":"https://doi.org/10.1136/annrheumdis-2012-eular.724","is_oa":false,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2012-eular.724","pdf_url":null,"source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"R. Fogel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Fogel","raw_affiliation_strings":["Pfizer, Collegeville"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Collegeville","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014587154","display_name":"S. Sridharan","orcid":"https://orcid.org/0009-0004-6139-8136","observed_orcids":["https://orcid.org/0009-0004-6139-8136"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Sridharan","raw_affiliation_strings":["Pfizer, Collegeville"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Collegeville","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060005100","display_name":"C. Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Li","raw_affiliation_strings":["Pfizer, Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Cambridge","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036308659","display_name":"Jodi Bradley","orcid":"https://orcid.org/0000-0002-4887-778X","observed_orcids":["https://orcid.org/0000-0002-4887-778X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Bradley","raw_affiliation_strings":["Pfizer, Groton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Groton, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072429797","display_name":"Richard J. Riese","orcid":"https://orcid.org/0009-0000-3657-6229","observed_orcids":["https://orcid.org/0009-0000-3657-6229"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Riese","raw_affiliation_strings":["Pfizer, Groton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Groton, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109127088","display_name":"Robert R. LaBadie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Labadie","raw_affiliation_strings":["Pfizer, Groton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Groton, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111827332","display_name":"S. Menon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Menon","raw_affiliation_strings":["Pfizer, Groton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Groton, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066093803","display_name":"Preeta Gupta","orcid":"https://orcid.org/0009-0005-3907-0027","observed_orcids":["https://orcid.org/0009-0005-3907-0027"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Gupta","raw_affiliation_strings":["Pfizer, Groton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Groton, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083669908","display_name":"S. Krishnasawami","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Krishnasawami","raw_affiliation_strings":["Pfizer, Groton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Groton, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090265370","display_name":"JEAN SACCUZZO BEEBE","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Beebe","raw_affiliation_strings":["Pfizer, Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Cambridge","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":null,"first_page":"680","last_page":"680"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.7685999870300293,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.7685999870300293,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.09239999949932098,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.06800000369548798,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.8479999899864197},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9449999928474426},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":1.0},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.8080000281333923},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.7509999871253967},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.7760000228881836},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6809999942779541},{"id":"https://openalex.org/keywords/first-in-human-safety","display_name":"first-in-human safety","score":0.6150000095367432},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6660000085830688},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.6790000200271606},{"id":"https://openalex.org/keywords/neutrophil-count","display_name":"neutrophil count","score":0.609000027179718},{"id":"https://openalex.org/keywords/inflammatory-diseases","display_name":"inflammatory diseases","score":0.6549999713897705},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.5559999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8648195266723633},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7910416722297668},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7809086441993713},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7358161211013794},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5996327996253967},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5659165978431702},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5351287722587585},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.48328521847724915},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4606355130672455},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4186001420021057},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.40114015340805054},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3719073534011841},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3718133270740509},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.1640087366104126},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/annrheumdis-2012-eular.724","doi":"https://doi.org/10.1136/annrheumdis-2012-eular.724","is_oa":false,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2012-eular.724","pdf_url":null,"source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2804752108","https://openalex.org/W1524102446","https://openalex.org/W3116870415","https://openalex.org/W2808194525","https://openalex.org/W2047402683","https://openalex.org/W4323320015","https://openalex.org/W1959530901","https://openalex.org/W4391529412","https://openalex.org/W1541406077","https://openalex.org/W2916905588"],"abstract_inverted_index":null,"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}